Status:
COMPLETED
A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease
Lead Sponsor:
UCB Pharma
Conditions:
Parkinson's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to assess whether it is possible for subjects with idiopathic Parkinson's Disease to switch from ropinirole, pramipexole and cabergoline to rotigotine transdermal system (...
Eligibility Criteria
Inclusion
- Idiopathic Parkinson's disease
Exclusion
- Not taking a dopamine agonist
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00242008
Start Date
December 1 2004
End Date
July 1 2005
Last Update
September 25 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schwarz
RTP, North Carolina, United States